KRAS and colorectal carcinoma: The results provided evidence that using the Activating KRAS Detection Chip in clinical contexts has the potential to increase the accuracy of chemotherapy efficacy predictions for stage III CRC patients receiving chemotherapy plus cetuximab treatment.